Clinical Trial Update: Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether combining chidamide and a PD-1 inhibitor can improve the efficacy of CAR-T cell therapy in relapsed or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CAR-T cell therapy
• Chidamide (chidamide)
• PD-1 inhibitor

Snippet

Sponsor: Daihong Liu | Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 2 | Status: RECRUITING